NeoChord
neochord.com
Actively hiring
Managed Security
Security Operations
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$122.9M
12 rounds on record
Latest round
$493k
Convertible Note · Feb 2025 · 19 mo ago
Team
12
US Form 5500 (plan participants) · Dec 2025 · -8% in a year
Backers
1
USVP
The money's age
Due for its next round
19 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 27, 2025
Raised a round Convertible Note $493k · SEC Form D
Aug 16, 2024
Raised a round Convertible Note $914k · SEC Form D
Feb 22, 2024
New executive NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitati… · PRNewswire
Jun 20, 2023
Raised a round Convertible Note $4.6M · SEC Form D
Sep 8, 2022
Raised a round Convertible Note $2.9M · SEC Form D
Feb 23, 2022
Raised a round Convertible Note $1.8M · SEC Form D
Sep 10, 2021
Raised a round Convertible Note $1M · SEC Form D
Apr 27, 2021
Raised a round Convertible Note $2.8M · SEC Form D
Oct 31, 2018
Raised a round Venture round $33.4M · SEC Form D
Oct 31, 2018
Raised a round Venture round $33.4M · SEC Form D
Sep 1, 2017
Raised a round Convertible Note $4M · SEC Form D
May 12, 2016
Certified NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation · businesswire.com
Oct 20, 2015
New executive NeoChord Appoints Lori Adels, Ph.D. as Vice President of Clinical Affairs, Regulatory and Quality · businesswire.com
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Feb 2025 | $493k | — | SEC Form D |
| Convertible Note | Aug 2024 | $914k | — | SEC Form D |
| Convertible Note | Jun 2023 | $4.6M | — | SEC Form D |
| Convertible Note | Sep 2022 | $2.9M | — | SEC Form D |
| Convertible Note | Feb 2022 | $1.8M | — | SEC Form D |
| Convertible Note | Sep 2021 | $1M | — | SEC Form D |
| Convertible Note | Apr 2021 | $2.8M | — | SEC Form D |
| Series D | Nov 2018 | $25M | — | neochord.com |
| Venture round | Oct 2018 | $33.4M | — | SEC Form D |
| Venture round | Oct 2018 | $33.4M | — | SEC Form D |
| Convertible Note | Sep 2017 | $4M | — | SEC Form D |
| Venture round | May 2015 | $12.6M | — | MedCity News |
Registers and programsofficial lists and records that name the company
| Legal entity | NEOCHORD INC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Ron NelsonExecutive OfficerSEC Form D
David ChungExecutive Officer, DirectorSEC Form D
Todd BergExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
USVP Similar startupsby what they do, their industry and backers
Cincinnati-based surgical procedure company focused on innovative development, commercialization of medical devices for treatment of…
New: 100 biomarkers for $190 SDNN = sqrt(Σ(NN_i - mean(NN))² / (N - 1))\n\nHere's an example. Let's say your heart is beating around 60bpm.
Become part of Europe’s fastest growing cybersecurity platform. Best-of-breed MDR. Expert-led 24/7 SOC. Incident response. Cyber insurance.
LimaCharlie is the agentic SecOps platform for MSSPs and MDRs: telemetry, detection, and response across every client you serve, on…
Wirespeed is the world's fastest SOC. Onboard in minutes, contain threats in milliseconds.
Hunters builds an artificial intelligence security operations platform that correlates telemetry into attack stories automatically. Founded…
News
NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation
/PRNewswire/ -- NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment...
Read more
Report
NeoChord Announces Positive 30-day Results with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor
ST. LOUIS PARK, Minn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced positive 30-
Read more
Report
NeoChord Announces Successful Completion of First-in-Human Procedure with its Mitral Chordal Repair Technology
Read more
Report
NeoChord System as an Alternative Option Upon Transmitral Pressure Gradient Elevation in the MitraClip Procedure
March 2020 CLICK FOR RELEASE The post NeoChord System as an Alternative Option Upon Transmitral Pressure Gradient Elevation in the MitraClip Procedure appeared first on NeoChord.
Read more
Report
Direct Beating Heart NeoChord Mitral Valve Re-Repair from Dr. Albertini/Cotignola
May 2020 CLICK FOR RELEASE The post Direct Beating Heart NeoChord Mitral Valve Re-Repair from Dr. Albertini/Cotignola appeared first on NeoChord.
Read more
Report
Pro access
Upgrade to see all 20 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Ron Nelson
Executive Officer
David Chung
Executive Officer, Director
Todd Berg
Executive Officer, Director
J. Martin
Director
Nicole Walker
Director
Andrew ElBardissi
Director
Michael Fulton
Director
Casey Tansey
Director
Mudit Jain
Director
Michael Liang
Director
David Gregorka
Director
David Neustaedter
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
St. Louis Park
United States
HQ
Maple Grove
United States
Regional office
CONTACT
10900 73rd Ave North Suite 101, Maple Grove, MN 55369
Financials
Total raised
$122.9M
Latest round
Convertible Note
Funding rounds
12
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Convertible Note | 2025 | $493k | Details |
| Convertible Note | 2024 | $914k | Details |
| Convertible Note | 2023 | $4.6M | Details |
| Convertible Note | 2022 | $2.9M | Details |
| Convertible Note | 2022 | $1.8M | Details |
| Convertible Note | 2021 | $1M | Details |
| Convertible Note | 2021 | $2.8M | Details |
| Series D | 2018 | $25M | Details |
| Venture - Series Unknown | 2018 | $33.4M | Details |
| Venture - Series Unknown | 2018 | $33.4M | Details |
| Convertible Note | 2017 | $4M | Details |
| Venture - Series Unknown | 2015 | $12.6M | Details |